Apple hit with $634 million verdict in Apple Watch patent fight with Masimo

A federal jury in California has awarded Masimo $634 million in damages, ruling that Apple infringed on a Masimo patent concerning the Apple Watch's blood oxygen feature. The verdict, which impacts 43 million Apple Watch units, centered on the jury's finding that the device qualifies as a "patient monitor" under the patent's terms. Apple, which had argued for significantly lower damages and stated the patent expired in 2022, plans to appeal this decision, which represents a notable financial liability and a significant win for Masimo in its intellectual property defense.

Analysis

A federal jury has awarded Masimo (MASI) $634 million in damages, finding that Apple (AAPL) infringed on Masimo's patent (no. 10,433,776) related to low power pulse oximeter features in the Apple Watch's blood oxygen sensor. This verdict, covering 43 million Apple Watch units, represents a substantial financial liability for Apple and a significant win for Masimo, aligning with Masimo's requested damages.

The core of the case centered on whether the Apple Watch qualifies as a "patient monitor" under Masimo's patent, a classification the jury ultimately affirmed despite Apple's arguments against continuous monitoring. Notably, the patent in question expired in 2022, a point Apple emphasized in its post-verdict statement.

Masimo has hailed this as a "significant win" for its intellectual property protection efforts, potentially bolstering its position in the healthcare technology sector. Apple, however, plans to appeal the verdict, asserting that the patent is specific to "historic patient monitoring technology" and that Masimo's prior legal challenges have often resulted in invalid patents. This legal battle is distinct from an ongoing International Trade Commission (ITC) dispute involving similar blood oxygen features.

Key Decisions for Investors

• Investors in Apple (AAPL) should closely monitor the appeal process, as a successful appeal could negate the $634 million liability, while an unsuccessful one would confirm the financial impact and potentially set a precedent for future intellectual property disputes.
• For Masimo (MASI), this verdict provides a significant financial boost and validates its intellectual property strategy, potentially enhancing its competitive standing in the medical device and health technology sectors, though the appeal introduces uncertainty regarding the final award.
• This case highlights the increasing legal and intellectual property risks associated with integrating advanced health monitoring features into consumer electronics, suggesting that companies in both technology and healthcare sectors may face heightened scrutiny and potential litigation over patent infringement.